KR880001302A - 피복 가능한 이온 교환 수지 - Google Patents

피복 가능한 이온 교환 수지 Download PDF

Info

Publication number
KR880001302A
KR880001302A KR1019870008332A KR870008332A KR880001302A KR 880001302 A KR880001302 A KR 880001302A KR 1019870008332 A KR1019870008332 A KR 1019870008332A KR 870008332 A KR870008332 A KR 870008332A KR 880001302 A KR880001302 A KR 880001302A
Authority
KR
South Korea
Prior art keywords
impregnating agent
drug
formulation
sorbitol
hydroxypropyl
Prior art date
Application number
KR1019870008332A
Other languages
English (en)
Other versions
KR960012067B1 (ko
Inventor
초우 산-라웅
라구나탄 예그나스와미
Original Assignee
마델린 알. 락스니스
펜월트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마델린 알. 락스니스, 펜월트 코포레이션 filed Critical 마델린 알. 락스니스
Publication of KR880001302A publication Critical patent/KR880001302A/ko
Application granted granted Critical
Publication of KR960012067B1 publication Critical patent/KR960012067B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Laminated Bodies (AREA)
  • Paints Or Removers (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyridine Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

내용 없음

Description

피복 가능한 이온 교환 수지
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 피복능이 증진되도록 히드록시프로필메틸 셀룰로오즈, 히드록시프로필 셀룰로오즈, 솔비톨, 히드록시프로필 솔비톨, 및 폴리비닐피롤리돈으로 이루어진 그룹 중에서 선택한 함침제 약 20중량% 이하(함침제 및 수지 입자의 합한 중량을 기준)로 처리한 설폰산 양이온 교환 수지 입자.
  2. 제1항에 있어서, 약물-수지 복합물 입자가 형성 되도록 기본 약물을 그위에 흡착시킨 수지 입자.
  3. 제2항에 있어서, 함침제로 처리한 다음, 수-투과성 확산 차단층으로 피복한 약물-수지 복합물 입자.
  4. 제3항에 피복된 약물-수지 복합물 입자로 이루어진 약제학적 제제.
  5. 제4항에 있어서, 함침제가 히드록시프로필메틸 셀룰로오즈인 제제.
  6. 제4항에 있어서, 함침제가 히드록시프로필 셀룰로오즈인 제제.
  7. 제4항에 있어서, 함침제가 솔비톨인 제제.
  8. 제4항에 있어서, 함침제가 히드록시프로필 솔비톨인 제제.
  9. 제4항에 있어서, 함침제가 폴리비닐피롤리돈인 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870008332A 1986-07-30 1987-07-30 피복가능한 이온 교환 수지 KR960012067B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89216986A 1986-07-30 1986-07-30
US892,169 1986-07-30
US892169 1986-07-30

Publications (2)

Publication Number Publication Date
KR880001302A true KR880001302A (ko) 1988-04-22
KR960012067B1 KR960012067B1 (ko) 1996-09-12

Family

ID=25399487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870008332A KR960012067B1 (ko) 1986-07-30 1987-07-30 피복가능한 이온 교환 수지

Country Status (13)

Country Link
EP (1) EP0254811B1 (ko)
JP (1) JP2670777B2 (ko)
KR (1) KR960012067B1 (ko)
AT (1) ATE93164T1 (ko)
AU (1) AU582302B2 (ko)
CA (1) CA1283998C (ko)
DE (1) DE3787060T2 (ko)
DK (1) DK394787A (ko)
FI (1) FI872582A (ko)
IE (1) IE62100B1 (ko)
IL (1) IL82223A0 (ko)
NO (1) NO873031L (ko)
NZ (1) NZ219816A (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US5149523A (en) * 1989-06-20 1992-09-22 Aktiebolaget Hassle Polystyrenesulfonate-drug complex and solid dosage forms thereof
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
JP3213712B2 (ja) * 1992-08-04 2001-10-02 全日本空輸株式会社 コンテナ自動移載装置および移載方法
JPH06305518A (ja) * 1993-04-23 1994-11-01 Kajima Corp 収納設備
WO1999020285A1 (fr) * 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Preparations de gels contenant un polystyrenesulfonate
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
JP3866179B2 (ja) 2002-10-09 2007-01-10 ダイセル化学工業株式会社 光学異性体分離用充填剤の製造方法
CA2509429A1 (en) 2002-11-26 2004-06-10 University Of Maryland, Baltimore Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
AU2004270188B8 (en) * 2003-09-03 2010-04-29 Mallinckrodt Inc. Granular sustained release preparation and production thereof
WO2006135362A1 (en) * 2005-06-09 2006-12-21 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB982150A (en) * 1961-09-29 1965-02-03 Glaxo Group Ltd Therapeutic resin complexes
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles

Also Published As

Publication number Publication date
AU7098987A (en) 1988-02-04
IE870789L (en) 1988-01-30
FI872582A (fi) 1988-01-31
NZ219816A (en) 1989-01-06
EP0254811A3 (en) 1989-04-05
DK394787D0 (da) 1987-07-29
JPS6335527A (ja) 1988-02-16
EP0254811A2 (en) 1988-02-03
KR960012067B1 (ko) 1996-09-12
CA1283998C (en) 1991-05-07
IL82223A0 (en) 1987-10-30
DE3787060T2 (de) 1993-12-02
AU582302B2 (en) 1989-03-16
NO873031L (no) 1988-02-01
FI872582A0 (fi) 1987-06-09
JP2670777B2 (ja) 1997-10-29
IE62100B1 (en) 1994-12-14
DE3787060D1 (de) 1993-09-23
DK394787A (da) 1988-05-02
NO873031D0 (no) 1987-07-20
ATE93164T1 (de) 1993-09-15
EP0254811B1 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
KR880001302A (ko) 피복 가능한 이온 교환 수지
DE3852781D1 (de) Präparat mit verzögerter Freisetzung sowie dessen Herstellung.
KR860000865A (ko) 약제 제형의 제조방법
KR880001288A (ko) 경구투여 형태의 서방성 약제학적 조성물
SE8404467D0 (sv) Controlled-release medical preparations
NO992994L (no) Legemidler mot hoste avlevert av ionebytterharpikser
KR830005850A (ko) 경구 투여용, 특히 소아경구 투여용 마이크로 캡슐화 바캄피실린산 부가염의 현탁액
KR960016882A (ko) 치주염치료를 위한 서방출형 생분해성 제제
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
IT1200424B (it) Fosforo rosso stabilizzato per uso come ritardante di fiamma,particolarmente per composizioni a base di polimeri
ES2052495T3 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
IT1215291B (it) Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
FI865227A0 (fi) Foerfarande foer framstaellning av ett depot-preparat.
DE69119810D1 (de) Pyrogensorbentmittel
KR880001732A (ko) 중합체-처리한 이온교환수지
NL175882B (nl) Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
GB1544761A (en) Prolonged release pharmaceutical preparations
ATE42894T1 (de) Fluessige pharmazeutische formulierungen mit verlaengerter wirkstofffreisetzung mit einem gehalt an ionischen bestandteilen.
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
NO960098L (no) Preparat i form av matriks-innesluttede små perler
DE69529079D1 (de) Codein enthaltende formulierungen
SE8902699D0 (sv) Diltiazem containing pharmaceutical compositios
BR0115206A (pt) Composições hidroliticamente instáveis
IT8220583A0 (it) Complessi organometallici di n-cicloesil-piperazino-acetammidi o propionammidi, loro preparazione e impiego come farmaci antiulcera-antisecretivi-tamponanti .
JPS56100715A (en) Plaster

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030903

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee